Huntsman Cancer Institute (HCI) seeks to establish itself as a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS) to provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. HCI is the only academic medical center and the only NCI-Designated Cancer Center in the Intermountain West, drawing clinical trials patients from across Utah as well as from Idaho, Nevada, and Wyoming, where no academic medical centers exist The HCI NLAPS will provide scientific leadership in development and conduct of clinical trials in association with SWOG, NRG, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS leadership team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in RTOG and GOG. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized single-point-of-service infrastructure for the clinical research enterprise. Our Center also has unique assets that are valuable for clinical research efforts, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful research linkage of population-based genealogical data and statewide medical records. HCI has a strong, established commitment to participation in cooperative group clinical trials: 35% of HCI therapeutic accruals are annually made to NCTN trials and, consistently, >50 NCTN therapeutic trials are open. HCI's participation in NCTN research has grown: in 2007, 95 patients were enrolled on therapeutic NCTN trials;in 2012, HCI will reach >150 therapeutic NCTN enrollments. In 2011, HCI was the second leading site for SWOG accruals overall and the sixth leading site for the three cooperative groups merging to form NRG. HCI would be a strong partner to the NCTN program through its efforts as a Cancer Center characterized by expertise, leadership, and active accrual.

Public Health Relevance

Huntsman Cancer Institute (HCI) will provide leadership in the development, conduct, and oversight of NCTN cooperative clinical trials, comprehensive support for the network, robust accruals to a broad array of trials, including trials in rare cances, and unique assets that can contribute value to the NCTN Program. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to eradicate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180818-01
Application #
8605363
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2014-04-15
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Gaffney, David K; Hashibe, Mia; Kepka, Deanna et al. (2018) Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol 151:547-554
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753

Showing the most recent 10 out of 37 publications